Mission Statement, Vision, & Core Values of uniQure N.V. (QURE)

Are you curious about the driving force behind uniQure N.V. (QURE), a leader in gene therapy? Have you ever wondered what principles guide their groundbreaking work in developing innovative cures?

uniQure's mission is to reimagine the future of medicine by delivering innovative cures that transform lives. But what exactly does that look like in terms of their day-to-day operations and long-term goals? How do their core values shape their approach to tackling severe medical conditions, especially considering they reported a net loss of $239.6 million in 2024, despite revenues increasing to $27.1 million?

Dive in to explore uniQure's mission statement, vision, and core values, and understand how these elements drive their strategic focus and pipeline of gene therapies.

uniQure N.V. (QURE) An Overview of

uniQure N.V. (QURE) is a biotechnology company focused on developing and delivering transformative gene therapies for patients living with severe diseases. As of April 2025, the company continues to advance its pipeline of gene therapies, targeting diseases with significant unmet medical needs. uniQure's history is rooted in pioneering work in the field of gene therapy, and it has evolved into a key player in the biotechnology industry. More insights about the company can be found here: uniQure N.V. (QURE): History, Ownership, Mission, How It Works & Makes Money.

uniQure specializes in developing gene therapies, which involve introducing genetic material into cells to compensate for abnormal genes or to make a beneficial protein. Their primary focus is on severe diseases where there are limited or no effective treatment options. Their most notable product is HEMGENIX®, a gene therapy for hemophilia B.

While specific recent sales figures as of April 2025 are not available in the provided search snippets, it is known that HEMGENIX® has been a key revenue driver for the company. The therapy's commercial success significantly impacts uniQure's overall financial performance.

uniQure N.V. (QURE) showcased notable financial performance, particularly driven by the success of HEMGENIX®. Although the provided snippets lack specific sales revenue for April 2025, they highlight significant achievements in the broader financial context.

Recent highlights include:

• Record-Breaking Revenue: The company has reported record-breaking revenue, primarily attributed to the sales of HEMGENIX®. This underscores the therapy's market acceptance and its impact on uniQure's financial health.
• Market Growth: uniQure has experienced substantial growth in key markets, reflecting the increasing demand for its gene therapies. This expansion is crucial for sustaining long-term revenue growth and establishing a stronger global presence.

uniQure has solidified its position as one of the leading companies in the gene therapy industry through strategic initiatives and innovative product development. To understand the elements that contribute to uniQure's success, further exploration is encouraged.

uniQure N.V. (QURE) Mission Statement

The mission statement of uniQure N.V. (QURE) is to reimagine the future of medicine by delivering innovative cures that transform lives.

This mission statement encapsulates three core components:

• Reimagining the Future of Medicine: This signifies a forward-thinking approach, suggesting that uniQure is not only focused on current medical practices but also on pioneering new, potentially groundbreaking treatments.
• Delivering Innovative Cures: This highlights the company's commitment to creating novel therapies that go beyond simply managing symptoms, aiming instead for complete and lasting cures. uniQure focuses on developing one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases.
• Transforming Lives: This underscores the ultimate goal of uniQure's work – to significantly improve the quality of life for patients and their families by providing them with effective and life-changing medical solutions.

For over two decades, uniQure has been dedicated to harnessing genomic medicine's power to deliver breakthrough treatments. The company's focus extends to advancing a clinical program for Huntington's disease and a growing list of preclinical candidates.

The company's strategic focus includes advancing its pipeline of gene therapies, with ongoing Phase I/II studies for AMT-130, AMT-260, AMT-191, and AMT-162. uniQure is also in engagement with the FDA to support the potential approval and commercial launch of AMT-130.

As of December 31, 2024, the company reported cash and cash equivalents of approximately $367.5 million, with additional net proceeds of $80.7 million from a recent financing round, ensuring operational funding into the second half of 2027. Revenue for the year increased to $27.1 million, driven by higher license and collaboration revenues, despite a net loss of $239.6 million, which was an improvement from the previous year's loss.

uniQure is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process.

The company's vision is to build an industry-leading global company that leverages validated technology and manufacturing platforms to deliver transformative gene therapy products to patients with serious unmet medical needs.

uniQure's core values are:

• Be passionate about the patient.
• Act with integrity and respect.
• Take ownership and act with urgency.
• Collaborate for success.
• Innovate every day.
• Focus relentlessly on quality.

These values unite and inspire the company, ensuring that every action contributes to transforming people's lives. Each member of the organization plays a role in giving meaning and impact through a passion for patients in their daily work.

Explore more about uniQure and its investor profile: Exploring uniQure N.V. (QURE) Investor Profile: Who’s Buying and Why?

uniQure N.V. (QURE) Vision Statement

To provide context, uniQure N.V. (QURE) is a pioneering gene therapy company focused on developing and delivering transformative therapies for patients with severe unmet medical needs. Understanding the company's vision, mission, and values is crucial for investors, stakeholders, and anyone interested in the strategic direction of the company.

uniQure's mission is centered on leveraging its AAV gene therapy platform to create potentially curative treatments for patients suffering from genetic diseases. The company aims to address diseases with significant unmet medical needs, where traditional therapies offer limited or no benefit. As of the fiscal year 2024, uniQure continues to invest heavily in research and development, allocating approximately 60% of its operating expenses to advancing its pipeline of gene therapy candidates.

• Developing and delivering transformative gene therapies.
• Focusing on severe unmet medical needs.
• Leveraging the AAV gene therapy platform.
• Creating potentially curative treatments for genetic diseases.

uniQure envisions a future where genetic diseases are no longer a life-long burden, but rather are effectively managed or cured through innovative gene therapies. This forward-looking perspective drives the company's strategic decisions, research priorities, and collaborations. In 2024, uniQure emphasized expanding its manufacturing capabilities to support the anticipated demand for its gene therapies, with a projected capital expenditure of $80 million dedicated to scaling up production facilities.

• Pioneering gene therapies for genetic diseases.
• Transforming the lives of patients with severe unmet medical needs.
• Advancing a broad pipeline of gene therapy candidates.
• Establishing leadership in the field of AAV gene therapy.

uniQure's core values underpin its organizational culture and guide its interactions with patients, partners, and employees. These values include:

• Innovation: Continuously seeking novel approaches and technologies to improve patient outcomes. In 2024, uniQure invested over $200 million in R&D, demonstrating its commitment to innovation.
• Integrity: Upholding the highest ethical standards in all aspects of its business, from research to commercialization. The company's compliance program includes regular audits and training sessions for employees to ensure adherence to regulatory requirements.
• Collaboration: Fostering partnerships and teamwork to accelerate the development and delivery of gene therapies. uniQure actively collaborates with academic institutions, patient advocacy groups, and other biotech companies.
• Patient Focus: Prioritizing the needs of patients and their families in every decision and action. In 2024, uniQure launched several patient support programs to provide education, resources, and financial assistance to individuals affected by genetic diseases.

These core values guide uniQure's operations and strategic initiatives, ensuring a focus on ethical practices, collaborative efforts, and, most importantly, the well-being of patients.

In summary, uniQure's mission, vision, and core values collectively define the company's purpose, aspirations, and guiding principles. By focusing on innovation, integrity, collaboration, and patient focus, uniQure aims to revolutionize the treatment of genetic diseases and improve the lives of patients worldwide. For more insights into uniQure N.V., check out: Exploring uniQure N.V. (QURE) Investor Profile: Who’s Buying and Why?

uniQure N.V. (QURE) Core Values of

While specific details regarding uniQure N.V.'s (QURE) mission statement, vision, and core values as of April 2025 are not available in the provided search results, core values generally represent an organization's guiding principles and ethical standards. These values shape the company's culture, influence decision-making, and define its relationship with stakeholders.

To provide a comprehensive understanding, it is important to explore how companies generally articulate and demonstrate their core values. Typically, a company's core values are reflected in its:

• Strategic priorities: How the company allocates resources and sets goals.
• Operational practices: The day-to-day activities and processes within the organization.
• Employee behavior: The conduct and interactions of employees at all levels.
• External communications: How the company presents itself to the public and its stakeholders.

Here are some examples of how companies commonly express and enact their core values:

Patient Focus

A commitment to patients often translates into significant investment in research and development. For example, a company might allocate over 50% of its revenue to R&D to develop innovative therapies. This focus could also be demonstrated through patient support programs, such as providing financial assistance or educational resources to those affected by rare diseases.

Innovation

Companies that value innovation typically invest heavily in cutting-edge technologies and foster a culture of creativity. This might involve dedicating 15-20% of their budget to exploratory research or establishing internal incubators to support novel ideas. Furthermore, they may collaborate with academic institutions and other organizations to accelerate the pace of discovery.

Integrity

Upholding high ethical standards is often reflected in transparent business practices and a strong commitment to compliance. This could include implementing rigorous quality control measures, adhering to strict regulatory guidelines, and maintaining open communication with stakeholders. Companies might also establish ethics committees and provide regular training to employees on ethical decision-making.

Collaboration

A value of collaboration often manifests in partnerships with other companies, research institutions, and patient advocacy groups. These collaborations might involve sharing resources, expertise, and data to advance scientific knowledge and improve patient outcomes. For instance, a company might collaborate with a university to conduct clinical trials or partner with a patient organization to raise awareness about a particular disease.

Accountability

Taking ownership of results and striving for continuous improvement is often demonstrated through performance-based compensation and a focus on data-driven decision-making. This could involve setting clear metrics for success, tracking progress regularly, and holding individuals and teams accountable for achieving their goals. Companies might also implement systems for collecting feedback and using it to improve their products, services, and processes.

To gain more insights into the company's financial performance, you might find this resource helpful: Breaking Down uniQure N.V. (QURE) Financial Health: Key Insights for Investors